Nov 27 (Reuters) - Xenon Pharmaceuticals Inc (XENE.O) :
<ul>
<li>XENON PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT X-NOVA CLINICAL TRIAL OF XEN1101 IN MAJOR DEPRESSIVE DISORDER (MDD)</li>
<li>XENON PHARMACEUTICALS INC - STATISTICAL SIGNIFICANCE WAS ACHIEVED ON KEY SECONDARY ENDPOINT OF A CHANGE IN SNAITH-HAMILTON PLEASURE SCALE</li>
<li>XENON PHARMACEUTICALS INC - XEN1101 WAS WELL TOLERATED WITH SIMILAR RATES OF ADVERSE EVENTS REPORTED ACROSS ALL TREATMENT ARMS</li>
<li>XENON PHARMACEUTICALS INC - STATISTICAL SIGNIFICANCE WAS ACHIEVED IN MADRS AT WEEK 1</li>
<li>XENON - CLEAR DOSE RESPONSE &amp; CLINICALLY MEANINGFUL, NOT STATISTICALLY SIGNIFICANT, 3.04 DIFFERENCE BETWEEN PLACEBO &amp; XEN1101 20 MG GROUP OBSERVED</li>
<li>XENON PHARMACEUTICALS INC - STATISTICAL SIGNIFICANCE WAS ACHIEVED ON PRE-SPECIFIED ENDPOINT OF HAMILTON DEPRESSION RATING SCALE, OR HAM-D17, AT WEEK 6</li>
<li>XENON PHARMACEUTICALS INC - XEN1101 WAS NOT ASSOCIATED WITH CLINICALLY MEANINGFUL WEIGHT GAIN OR SEXUAL DYSFUNCTION</li>
</ul>

XENE

Nov 27 (Reuters) - Xenon Pharmaceuticals Inc (XENE.

Xenon Pharmaceuticals Announces Topline Results From Phase 2 Proof-Of-Concept X-NOVA Clinical Trial Of XEN1101 In Major Depressive Disorder